Form 4: Passage Bio, Inc. Executive Granted Stock Options

Chief Medical Officer Mark S. Forman receives stock options for 203,000 shares of Passage Bio, Inc. common stock.

Summary

• Mark S. Forman, Chief Medical Officer of Passage Bio, Inc., was granted stock options on March 15, 2024.
• The options are for 203,000 shares of Passage Bio, Inc. common stock.
• The exercise price of the options is $1.50 per share.
• The options vest monthly, starting April 15, 2024, over a period of 48 months, contingent upon continued service to the Issuer.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral positive.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The vesting schedule suggests a commitment to long-term value creation by the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant and vesting schedule are typical for a Chief Medical Officer role, but would need to be compared to similar companies of the same market cap and stage of development to determine if it is above or below industry averages.
• Companies like BioMarin Pharmaceutical Inc. and Sarepta Therapeutics, Inc. also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
• Employees may see this as a positive sign of investment in leadership.

Key Dates